| IPO Company Profile © ipodata.com |
| Message Board | Quote | Chart | News | SEC Filings | Peer IPO Companies |
| Third Wave Technologies, Inc. |
| 502 South Roas Road, Madison, WI 53719 * (608) 273-8933 |
| Business Description | The company is a leading provider of products for analyzing genetic variations. |
| Offering Information Company has | |||
| Trading As | TWTI (NASNTL) | Industry | Pharmaceutical (SIC 2836) |
| Type of Stock Offered | Common Shares | Filing Date | 7/31/2000 |
| Domestic Shares Offered | 7,500,000 | Offer Date | 2/8/2001 |
| Foreign Shares Offered | 0 | Filing Range | $11.00 - $13.00 |
| Company Shares | 7,500,000 | Offer Price | $11.00 |
| Selling Shrhldrs Shares | 0 | Gross Spread | $0.770 |
| Gross Proceeds | $82,500,000 | Selling | $0.440 |
| Expenses | - - | Reallowance | $0.100 |
| Post-IPO Shares | - - | Employees | - - |
| Primary Underwriting Group | ||
| Underwriter Name | Participation | Underwriter Phone |
| Lehman Brothers Incorporated | Lead Manager | (212) 526-8100 |
| CIBC World Markets | Co-manager | (212) 667-7400 |
| Dain Rauscher Wessels | Co-manager | (612) 371-2818 |
| Fidelity Capital Markets | Co-manager | |
| Robert W. Baird & Company | Co-manager | (414) 765-3632 |
| Income Statement and Cash Flow Summary | |||||||
| Prior Audited Income |
Latest Unaudited Income | ||||||
| Full Year Audited Figures | 6 Months Ending | ||||||
| Figures in U.S. millions except per share data | 12/31/1995 | 12/31/1996 | 12/31/1997 | 12/31/1998 | 12/31/1999 | 6/30/1999 | 6/30/2000 |
| Revenues | 1.129 | 2.154 | 1.119 | 4.382 | 2.574 | 1.675 | 1.374 |
| Income from Oper. | -0.697 | -1.881 | -5.116 | -5.579 | -9.794 | -3.420 | -16.701 |
| Net Income | -0.699 | -1.522 | -4.899 | -5.432 | -9.228 | -3.356 | -16.594 |
| E.P.S | - | - | - | - | - | - | - |
| Revenue Growth (%) | 90.79 | -48.05 | 291.60 | -41.260 | -17.97 | ||
| Net Income Growth (%) | - | - | - | - | - | ||
| Oper. Profit Margin (%) | - | - | - | - | - | - | - |
| Net Profit Margin (%) | - | - | - | - | - | - | - |
| Cash Flow - Oper. | -8.93 | -4.02 | -11.58 | ||||
| Cash Flow - Inv. | -0.79 | 3.35 | -7.43 | ||||
| Cash Flow - Fin. | 18.94 | 0.49 | 10.89 | ||||
| Balance Sheet Summary and Financial Ratios | |||||
| Balance sheet as of: 6/30/2000 | Financial Ratios | ||||
| Total Assets | 17.25 | Current Assets | 9.20 | Current Ratio | 0.99 |
| Total Liab. | 15.94 | Current Liab. | 9.25 | Debt Ratio | 92.40% |
| Total Equity | 1.31 | Working Cap. | -0.05 | Debt to Equity Ratio | 12.15 |
| Cash | 2.00 | Return on Assets | - | ||
| Use Of Proceeds |
The proceeds from the proposed offering will be used for general corporate purposes, including working capital, research and development activities and potential acquisitions. |
| Legal Counsel Registrar Auditor | |
| Issuer's Law Firm | Wilson, Sonsini, Goodrich & Rosati |
| Bank's Law Firm | Mintz, Levin, Cohn, Ferris, Glovsky And Popeo |
| Auditor | Ernst & Young |
| Send us feedback if you would like to request that we hyperlink a firm on this page | |
| Principal Shareholders | ||
| Name of Shareholder | % Owned Before | % Owned After |
| Wellcome Trust Limited, The | ||
| Note: represents ownership of 5% or more prior to the offering. | ||